Last reviewed · How we verify

morphine ,ketorolac

Jose Antonio Bernia Gil · FDA-approved active Small molecule

This is a combination of morphine (an opioid agonist) and ketorolac (an NSAID) that work together to provide analgesia through different pathways.

This is a combination of morphine (an opioid agonist) and ketorolac (an NSAID) that work together to provide analgesia through different pathways. Used for Moderate to severe acute pain, Postoperative pain.

At a glance

Generic namemorphine ,ketorolac
SponsorJose Antonio Bernia Gil
Drug classOpioid analgesic + NSAID combination
TargetOpioid receptors (μ, δ, κ); COX-1 and COX-2 enzymes
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Morphine binds to opioid receptors in the central nervous system to reduce pain perception and emotional response to pain. Ketorolac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and peripheral inflammation. Together, they provide multimodal analgesia for moderate to severe pain.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: